Free Trial
NASDAQ:XBIO

Xenetic Biosciences (XBIO) Stock Price, News & Analysis

Xenetic Biosciences logo
$3.20 -0.04 (-1.20%)
As of 08/1/2025 03:55 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Xenetic Biosciences Stock (NASDAQ:XBIO)

Key Stats

Today's Range
$3.05
$3.43
50-Day Range
$2.74
$4.11
52-Week Range
$2.20
$5.27
Volume
21,332 shs
Average Volume
52,563 shs
Market Capitalization
$4.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Hold

Company Overview

Xenetic Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
18th Percentile Overall Score

XBIO MarketRank™: 

Xenetic Biosciences scored higher than 18% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Earnings Growth

    Earnings for Xenetic Biosciences are expected to grow in the coming year, from ($1.01) to ($0.66) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Xenetic Biosciences is -1.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Xenetic Biosciences is -1.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Xenetic Biosciences has a P/B Ratio of 0.82. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Xenetic Biosciences' valuation and earnings.
  • Percentage of Shares Shorted

    2.62% of the float of Xenetic Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Xenetic Biosciences has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Xenetic Biosciences has recently increased by 69.95%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Xenetic Biosciences does not currently pay a dividend.

  • Dividend Growth

    Xenetic Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.62% of the float of Xenetic Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Xenetic Biosciences has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Xenetic Biosciences has recently increased by 69.95%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Xenetic Biosciences has a news sentiment score of -0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Xenetic Biosciences this week, compared to 0 articles on an average week.
  • Search Interest

    Only 1 people have searched for XBIO on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Xenetic Biosciences to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Xenetic Biosciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    14.70% of the stock of Xenetic Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 15.12% of the stock of Xenetic Biosciences is held by institutions.

  • Read more about Xenetic Biosciences' insider trading history.
Receive XBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xenetic Biosciences and its competitors with MarketBeat's FREE daily newsletter.

XBIO Stock News Headlines

Xenetic Biosciences (XBIO) Receives a Hold from H.C. Wainwright
Is Elon's empire crumbling?
The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd.
Xenetic Biosciences Inc
3XB0.SG,0P0001N0OC,0 (3XB0.SG)
Xenetic Biosciences Inc (XBIO)
See More Headlines

XBIO Stock Analysis - Frequently Asked Questions

Xenetic Biosciences' stock was trading at $3.99 at the beginning of 2025. Since then, XBIO stock has decreased by 19.8% and is now trading at $3.2010.

Xenetic Biosciences, Inc. (NASDAQ:XBIO) announced its quarterly earnings data on Tuesday, May, 13th. The company reported ($0.59) EPS for the quarter, beating analysts' consensus estimates of ($0.72) by $0.13. The firm earned $0.59 million during the quarter, compared to the consensus estimate of $0.52 million. Xenetic Biosciences had a negative trailing twelve-month return on equity of 57.31% and a negative net margin of 142.10%.

Shares of Xenetic Biosciences reverse split on the morning of Monday, May 15th 2023.The 1-10 reverse split was announced on Monday, May 15th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Xenetic Biosciences' top institutional investors include Sachetta LLC (0.99%).

Shares of XBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Xenetic Biosciences investors own include FuelCell Energy (FCEL), OPKO Health (OPK), VBI Vaccines (VBIV), Bionano Genomics (BNGO), NIO (NIO), Sorrento Therapeutics (SRNE) and Vaxart (VXRT).

Company Calendar

Last Earnings
5/13/2025
Today
8/02/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:XBIO
CIK
1534525
Fax
N/A
Employees
4
Year Founded
2011

Profitability

EPS (Trailing Twelve Months)
($2.38)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$3.96 million
Net Margins
-142.10%
Pretax Margin
-142.06%
Return on Equity
-57.31%
Return on Assets
-49.30%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
8.20
Quick Ratio
8.20

Sales & Book Value

Annual Sales
$2.50 million
Price / Sales
1.97
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.89 per share
Price / Book
0.82

Miscellaneous

Outstanding Shares
1,540,000
Free Float
1,315,000
Market Cap
$4.93 million
Optionable
Not Optionable
Beta
2.32

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:XBIO) was last updated on 8/2/2025 by MarketBeat.com Staff
From Our Partners